Corticosteróides inalados no tratamento da alergia respiratória: segurança versus eficácia
Autor(a) principal: | |
---|---|
Data de Publicação: | 2006 |
Outros Autores: | |
Tipo de documento: | Artigo |
Idioma: | por |
Título da fonte: | Repositório Institucional da UNIFESP |
Texto Completo: | http://dx.doi.org/10.1590/S0021-75572006000700010 http://repositorio.unifesp.br/handle/11600/3336 |
Resumo: | OBJECTIVE: Review the molecular mechanisms of action, efficacy, and potential side effects associated with inhaled corticosteroids (ICS) in children with persistent asthma. SOURCES: Articles in English from MEDLINE. The following terms were used: corticosteroids, inhaled corticosteroids, asthma, children, beclomethasone, fluticasone, budesonide, ciclesonide, growth, adrenal insufficiency, bone mineral density, and oral candidiasis. Treatment guidelines, review articles, controlled trials, meta-analyses, and systematic reviews evaluating the efficacy and the adverse events of treatment with ICS were selected. SUMMARY OF THE FINDINGS: In vivo and in vitro studies show that the available ICS have different pharmacokinetic and pharmacodynamic properties that result in different action potentials. ICS also differ as to the systemic and local side effects. The bioavailability of these products is essential in order to determine the incidence of side effects. In general, ICS are capable of controlling asthma, reducing the number of exacerbations, medical consultations, hospitalizations, and the need of oral corticosteroid (applications) bursts. Improvement can also be seen in pulmonary function, especially in patients with recent onset asthma. The most documented adverse effect is transitory decrease of growth rate. CONCLUSIONS: ICS are the main anti-inflammatory agent used to treat persistent asthma. When administered in low doses, they seem to be safe and effective. Patient monitoring allows for early detection of possible side effects associated with ICS. |
id |
UFSP_1e25c002e09e0e1625f366aa0bf8acc2 |
---|---|
oai_identifier_str |
oai:repositorio.unifesp.br/:11600/3336 |
network_acronym_str |
UFSP |
network_name_str |
Repositório Institucional da UNIFESP |
repository_id_str |
3465 |
spelling |
Corticosteróides inalados no tratamento da alergia respiratória: segurança versus eficáciaInhaled corticosteroids in the treatment of respiratory allergy: safety vs. efficacyChildrenasthmainhaled corticosteroidsbudesonidebeclomethasonefluticasoneciclesonideCriançaasmacorticosteróides inaladosbudesonidabeclometasonafluticasonaciclenonidaOBJECTIVE: Review the molecular mechanisms of action, efficacy, and potential side effects associated with inhaled corticosteroids (ICS) in children with persistent asthma. SOURCES: Articles in English from MEDLINE. The following terms were used: corticosteroids, inhaled corticosteroids, asthma, children, beclomethasone, fluticasone, budesonide, ciclesonide, growth, adrenal insufficiency, bone mineral density, and oral candidiasis. Treatment guidelines, review articles, controlled trials, meta-analyses, and systematic reviews evaluating the efficacy and the adverse events of treatment with ICS were selected. SUMMARY OF THE FINDINGS: In vivo and in vitro studies show that the available ICS have different pharmacokinetic and pharmacodynamic properties that result in different action potentials. ICS also differ as to the systemic and local side effects. The bioavailability of these products is essential in order to determine the incidence of side effects. In general, ICS are capable of controlling asthma, reducing the number of exacerbations, medical consultations, hospitalizations, and the need of oral corticosteroid (applications) bursts. Improvement can also be seen in pulmonary function, especially in patients with recent onset asthma. The most documented adverse effect is transitory decrease of growth rate. CONCLUSIONS: ICS are the main anti-inflammatory agent used to treat persistent asthma. When administered in low doses, they seem to be safe and effective. Patient monitoring allows for early detection of possible side effects associated with ICS.OBJETIVO: Revisar os mecanismos moleculares de ação, eficácia e potenciais efeitos adversos relacionados aos corticosteróides inalados (CEI) em crianças com asma persistente. FONTES DOS DADOS: Artigos de língua inglesa da base de dados MEDLINE. Foram empregados os termos: corticosteroids, inhaled corticosteroids, asthma, children, beclomethasone, fluticasone, budesonide, ciclesonide, growth, adrenal insufficiency, bone mineral density, oral candidiasis. Foram selecionados guias de tratamento, artigos de revisão, estudos controlados, meta-análises e revisões sistemáticas que avaliaram a eficácia e os eventos adversos do tratamento com CEI. SÍNTESE DOS DADOS: Estudos in vivo e in vitro mostram que os CEI disponíveis apresentam diferentes características farmacocinéticas e farmacodinâmicas que lhes conferem diferentes potenciais de ação. Os CEI também diferem quanto aos efeitos adversos sistêmicos e locais. Salienta-se a biodisponibilidade desses produtos como essencial para determinar a incidência de efeitos colaterais. Em linhas gerais, os CEI são capazes de controlar a asma, reduzindo o número de exacerbações, atendimentos médicos, hospitalizações e a necessidade de pulsos de corticosteróides orais. Também se observa melhora da função pulmonar, sobretudo nos pacientes com asma de início recente. O efeito adversos mais documentado é a desaceleração transitória do ritmo de crescimento. CONCLUSÕES: Os CEI são o principal agente antiinflamatório utilizado no tratamento da asma persistente. Quando administrados em doses baixas, mostram-se seguros e efetivos. O monitoramento dos pacientes permite a detecção precoce de eventuais efeitos adversos associados aos CEI.Universidade Federal de São Paulo (UNIFESP) Escola Paulista de Medicina Departamento de PediatriaUNIFESP, EPM, Depto. de PediatriaSciELOSociedade Brasileira de PediatriaUniversidade Federal de São Paulo (UNIFESP)Rizzo, Maria Cândida V. [UNIFESP]Solé, Dirceu [UNIFESP]2015-06-14T13:36:31Z2015-06-14T13:36:31Z2006-11-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionS198-S205application/pdfhttp://dx.doi.org/10.1590/S0021-75572006000700010Jornal de Pediatria. Sociedade Brasileira de Pediatria, v. 82, n. 5, p. S198-S205, 2006.10.1590/S0021-75572006000700010S0021-75572006000700010.pdf0021-7557S0021-75572006000700010http://repositorio.unifesp.br/handle/11600/3336porJornal de Pediatriainfo:eu-repo/semantics/openAccessreponame:Repositório Institucional da UNIFESPinstname:Universidade Federal de São Paulo (UNIFESP)instacron:UNIFESP2024-07-28T11:47:24Zoai:repositorio.unifesp.br/:11600/3336Repositório InstitucionalPUBhttp://www.repositorio.unifesp.br/oai/requestbiblioteca.csp@unifesp.bropendoar:34652024-07-28T11:47:24Repositório Institucional da UNIFESP - Universidade Federal de São Paulo (UNIFESP)false |
dc.title.none.fl_str_mv |
Corticosteróides inalados no tratamento da alergia respiratória: segurança versus eficácia Inhaled corticosteroids in the treatment of respiratory allergy: safety vs. efficacy |
title |
Corticosteróides inalados no tratamento da alergia respiratória: segurança versus eficácia |
spellingShingle |
Corticosteróides inalados no tratamento da alergia respiratória: segurança versus eficácia Rizzo, Maria Cândida V. [UNIFESP] Children asthma inhaled corticosteroids budesonide beclomethasone fluticasone ciclesonide Criança asma corticosteróides inalados budesonida beclometasona fluticasona ciclenonida |
title_short |
Corticosteróides inalados no tratamento da alergia respiratória: segurança versus eficácia |
title_full |
Corticosteróides inalados no tratamento da alergia respiratória: segurança versus eficácia |
title_fullStr |
Corticosteróides inalados no tratamento da alergia respiratória: segurança versus eficácia |
title_full_unstemmed |
Corticosteróides inalados no tratamento da alergia respiratória: segurança versus eficácia |
title_sort |
Corticosteróides inalados no tratamento da alergia respiratória: segurança versus eficácia |
author |
Rizzo, Maria Cândida V. [UNIFESP] |
author_facet |
Rizzo, Maria Cândida V. [UNIFESP] Solé, Dirceu [UNIFESP] |
author_role |
author |
author2 |
Solé, Dirceu [UNIFESP] |
author2_role |
author |
dc.contributor.none.fl_str_mv |
Universidade Federal de São Paulo (UNIFESP) |
dc.contributor.author.fl_str_mv |
Rizzo, Maria Cândida V. [UNIFESP] Solé, Dirceu [UNIFESP] |
dc.subject.por.fl_str_mv |
Children asthma inhaled corticosteroids budesonide beclomethasone fluticasone ciclesonide Criança asma corticosteróides inalados budesonida beclometasona fluticasona ciclenonida |
topic |
Children asthma inhaled corticosteroids budesonide beclomethasone fluticasone ciclesonide Criança asma corticosteróides inalados budesonida beclometasona fluticasona ciclenonida |
description |
OBJECTIVE: Review the molecular mechanisms of action, efficacy, and potential side effects associated with inhaled corticosteroids (ICS) in children with persistent asthma. SOURCES: Articles in English from MEDLINE. The following terms were used: corticosteroids, inhaled corticosteroids, asthma, children, beclomethasone, fluticasone, budesonide, ciclesonide, growth, adrenal insufficiency, bone mineral density, and oral candidiasis. Treatment guidelines, review articles, controlled trials, meta-analyses, and systematic reviews evaluating the efficacy and the adverse events of treatment with ICS were selected. SUMMARY OF THE FINDINGS: In vivo and in vitro studies show that the available ICS have different pharmacokinetic and pharmacodynamic properties that result in different action potentials. ICS also differ as to the systemic and local side effects. The bioavailability of these products is essential in order to determine the incidence of side effects. In general, ICS are capable of controlling asthma, reducing the number of exacerbations, medical consultations, hospitalizations, and the need of oral corticosteroid (applications) bursts. Improvement can also be seen in pulmonary function, especially in patients with recent onset asthma. The most documented adverse effect is transitory decrease of growth rate. CONCLUSIONS: ICS are the main anti-inflammatory agent used to treat persistent asthma. When administered in low doses, they seem to be safe and effective. Patient monitoring allows for early detection of possible side effects associated with ICS. |
publishDate |
2006 |
dc.date.none.fl_str_mv |
2006-11-01 2015-06-14T13:36:31Z 2015-06-14T13:36:31Z |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://dx.doi.org/10.1590/S0021-75572006000700010 Jornal de Pediatria. Sociedade Brasileira de Pediatria, v. 82, n. 5, p. S198-S205, 2006. 10.1590/S0021-75572006000700010 S0021-75572006000700010.pdf 0021-7557 S0021-75572006000700010 http://repositorio.unifesp.br/handle/11600/3336 |
url |
http://dx.doi.org/10.1590/S0021-75572006000700010 http://repositorio.unifesp.br/handle/11600/3336 |
identifier_str_mv |
Jornal de Pediatria. Sociedade Brasileira de Pediatria, v. 82, n. 5, p. S198-S205, 2006. 10.1590/S0021-75572006000700010 S0021-75572006000700010.pdf 0021-7557 S0021-75572006000700010 |
dc.language.iso.fl_str_mv |
por |
language |
por |
dc.relation.none.fl_str_mv |
Jornal de Pediatria |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
S198-S205 application/pdf |
dc.publisher.none.fl_str_mv |
Sociedade Brasileira de Pediatria |
publisher.none.fl_str_mv |
Sociedade Brasileira de Pediatria |
dc.source.none.fl_str_mv |
reponame:Repositório Institucional da UNIFESP instname:Universidade Federal de São Paulo (UNIFESP) instacron:UNIFESP |
instname_str |
Universidade Federal de São Paulo (UNIFESP) |
instacron_str |
UNIFESP |
institution |
UNIFESP |
reponame_str |
Repositório Institucional da UNIFESP |
collection |
Repositório Institucional da UNIFESP |
repository.name.fl_str_mv |
Repositório Institucional da UNIFESP - Universidade Federal de São Paulo (UNIFESP) |
repository.mail.fl_str_mv |
biblioteca.csp@unifesp.br |
_version_ |
1814268270670249984 |